Expressing the Promise of Your Protein
Whether you are developing a Monoclonal Antibody, Recombinant Protein, Vaccine, or Antibody Drug Conjugate, you should consider Goodwin Biotechnology, Inc. (GBI) as your development partner.
Our Mission Statement
GBI is a world-class CMO that excels as a strategic partner to deliver the highest quality material from proof of concept through product for clinical trials by employing superior cGMP compliant services that enable cost-effective, on-time delivery of our client's pre-clinical and clinical supplies to enhance patient's lives.
Define Your Needs With GBI –
GBI is dedicated to partnering with you on your project, whether you are:
Our goal at GBI is to provide superior service to our clients that not only meets, but exceeds their expectations. We can be a one-stop shop or we can help determine where we can add the most value when you need us anywhere along the process:
2012 CMO Leadership AwardsFor more information, please see our Press Release
The Art of Bioconjugation
Conjugation of monoclonal antibodies and recombinant proteins with other molecules is a specialty of GBI's development and manufacturing groups. Whether the conjugate is a drug toxin (small molecule cancer drugs, plant protein toxins), chelating agents for radio isotopes labeling (diagnostics and therapeutics), adjuvants such as Aluminum Hydroxide-Antibody conjugate, or other antibodies, GBI has the ability to develop and perform them at GMP compliant manufacturing scales for clinical applications. For more information on our Bioconjugation experience, click here.
For more information on developing and manufacturing highly potent Cytotoxic Antibody Drug Conjugates, click here
Biologicals represent the fastest growing segment of the pharmaceutical market and over 30 branded biologics with sales in excess of $50 billion are facing patent expirations. That yields a significant business opportunity to develop Biosimilars.